TriangleTSR-042 or Dostarlimab (NCT04165772)
TSR-042 or Dostarlimab trial for Rectal Adenocarcinoma (NCT04165772). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with nonmetastatic, mismatch-repair-deficient or microsatellite-unstable solid tumors, without prior chemotherapy, radiation or surgery for that tumor. A separate group includes stage I–II endometrial cancer.
The idea: intravenous dostarlimab blocks PD-1 to release immune brakes. In the main cohort, complete responders can receive nonoperative monitoring; others may proceed to chemoradiation and then surgery, depending on response.
This phase 2 study plans 212 patients. Andrea Cercek leads at Memorial Sloan Kettering in New York. Ten US locations are marked recruiting; nine provide only limited activities or data collection.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.